What's Happening?
Segmed, Inc., a leader in real-world medical imaging and multimodal data for research and AI development, has announced a partnership with Verily, a precision health AI company. This collaboration aims to make Segmed's de-identified, diagnostic-grade
imaging and associated clinical data accessible through Verily's precision health platform. The platform, known as Pre Exchange and Workbench, is designed to accelerate precision health research and discovery. Segmed's initial dataset focuses on breast cancer and includes a longitudinal cohort of patients who underwent digital breast tomosynthesis exams. This partnership reflects Segmed's commitment to supporting privacy-first research and lowering barriers for investigators in academia, life sciences, and healthcare AI.
Why It's Important?
The partnership between Segmed and Verily is significant as it enhances the availability of high-quality, de-identified imaging datasets, which are crucial for precision medicine. By integrating these datasets into Verily's platform, researchers can generate insights faster, potentially accelerating the development of diagnostics and therapies. This collaboration supports patient-centered, data-driven healthcare innovation by enabling secure access to real-world imaging data. It also highlights the growing importance of AI in healthcare, as it allows for more personalized care and better disease management at a population level.
What's Next?
The collaboration is expected to lead to further advancements in precision health research. Researchers will have access to comprehensive, multimodal data resources, which could unlock new insights and accelerate discovery. As the partnership progresses, it may lead to the development of new diagnostics and therapies, ultimately improving patient outcomes. Additionally, the partnership may inspire similar collaborations in the healthcare industry, further integrating AI and data science into medical research and care.
